My watch list  


Systematic (IUPAC) name
CAS number 106133-20-4
ATC code G04CA02
PubChem 129211
DrugBank APRD00036
Chemical data
Formula C20H28N2O5S 
Mol. mass 408.51
Pharmacokinetic data
Bioavailability 100% (oral)
Metabolism hepatic
Half life 9–13 hours
Excretion 76% renal
Therapeutic considerations
Pregnancy cat.

B2 (Aust)

Legal status

Schedule 4 (Aust)

Routes oral

Tamsulosin (rINN) (pronounced /tæmˈsuːloʊsɪn/, /tæmsuˈloʊsɪn/) is an α1a-selective alpha blocker used in the symptomatic treatment of benign prostatic hyperplasia (BPH). Tamsulosin was developed by Yamanouchi Pharmaceuticals (now part of Astellas Pharma) and is marketed by various companies under licence, including Boehringer-Ingelheim and CSL. As of 2006, tamsulosin hydrochloride extended-release tablets are marketed under the trade name Flomaxtra. It was formerly marketed as modified-release capsules under the trade name Flomax.

Clinical use

Adverse effects

Two ADRs (Adverse Drug Reactions) have been reported:

  • Immunologic: It contains a sulfa moiety, thus causing typical reactions to sulfa drugs.
  • Ophthalmologic: Patients taking tamsulosin are prone to a complication known as floppy iris syndrome during cataract surgery. Adverse outcomes of the surgery are greatly reduced by the surgeon's prior knowledge of the patient's history with this drug, and thus having the option of alternative techniques. [1]

Tamsulosin has also affected the sexual function in men. Tamsulosin can cause males to experience retrograde ejaculation.

Clinical comparison

Although prostate specific, it does not have the prostate apoptotic effects of other alpha-blockers such as doxazosin and terazosin.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Tamsulosin". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE